A 12-week dose of an investigational three-drug hepatitis C combination cured the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study. For most of the past 20 years, therapies for hepatitis C relied on interferon drugs, which require regular injections for as long as one year and trigger miserable, flu-like side effects that prompt many patients to quit the regimen. Some patients aren't eligible for this treatment if they have anemia, low platelets or other conditions.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1EdO7Hj
No comments:
Post a Comment